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Dear Editor,
In  patients  with  chronic  liver  disease  (CLD),  liver  bi-
opsy is currently an indispensable reference method to 
assess inflammatory activity and fibrosis stage and thus 
to estimate prognosis and guide management decisions 
in such patients. Given that the presence of advanced fi-
brosis is a predictor of nonresponse, the decision (1) to 
begin antiviral therapy in cases of chronic viral hepati-
tis is highly influenced by the stage of liver fibrosis. For 
example, in chronic hepatitis C (CHC) patients, the stage 
of liver fibrosis is a predictor of response to interferon-
based  treatment.  Despite  these  premises,  liver  biopsy 
has several disadvantages, including poor patient com-
pliance,  sampling  error,  limited  usefulness  for  follow 
up, and poor intra- and interobservation agreements (2). 
Considering these limitations, in the last decade clinical 
investigators have been searching for noninvasive meth-
ods  to  obtain  accurate  information  about  the  fibrosis 
stage in patients with CLD. Accordingly, a noninvasive di-
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agnostic test for liver fibrosis should be simple, available 
to wide audiences at limited expense, able to accurately 
identify  disease  stage,  and  sensitive  enough  to  track 
changes in fibrosis induced by the natural course of dis-
ease progression or by therapy (3). Serum biochemical 
tests, including direct and indirect markers of liver fibro-
sis, have been the subject of an intensive investigation, 
but their diagnostic accuracy has been reported to vary 
widely (3, 4). In this area, of great contemporary interest 
is the article by Yilmaz et al. on the usefulness of the as-
partate transaminase to platelet ratio index (APRI) to as-
sess liver fibrosis in patients with CLD (5). APRI is a simple 
and cheap method to ascertain the ratio between AST and 
platelets and is easy to use in clinical practice. In patients 
with CHC, APRI performance has been reported to vary 
widely in diagnostic accuracy (sensitivities between 41% 
and 91% and specificities between 47% and 95%) for iden-
tifying significant fibrosis. A recent systematic review (6) 
showed that for significant fibrosis, an APRI threshold 
of 0.5 was 81% sensitive and 50% specific. Furthermore, 
Cheung et al. found that in patients with CHC, APRI was 
better in predicting advanced versus significant fibrosis, 
and the authors suggested that APRIs with a cutoff of 0.5 
and 1.5 can be used in routine clinical practice to exclude 
or identify the presence of advanced fibrosis (7).
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Consistent with the previous research, the retrospec-
tive study by Yilmaz et al. (5) showed that APRI has an ac-
ceptable accuracy for the assessment of liver fibrosis in 
patients with CHC but not in those with chronic hepati-
tis B (CHB). Indeed, in Yilmaz et al.’s study APRI was sig-
nificantly associated with fibrosis scores in subjects with 
CHC (p = 0.0059) but not in those with CHB (p = 0.1495). 
The major finding of their study was that the APRI also 
had an acceptable accuracy for the assessment of liver 
fibrosis in patients with nonalcoholic fatty liver disease 
(NAFLD), tending to increase with the degree of fibrosis. 
In previous observational studies that included patients 
with NAFLD, the APRI score seldom reached the value of 1 
but tended to be higher in patients with advanced stages 
of fibrosis (8). In the early stages of NAFLD, patients usu-
ally present mild to moderate increases in aminotrans-
ferase levels, while platelet counts are usually normal. Fi-
brosis progresses over time, but it may remain stable for 
some years. Thus, the focus of the study by Yilmaz et al. (5) 
is that the APRI may be a useful asset in clinical practice to 
identify the natural course of NAFLD as it approaches the 
advanced stages. Nonetheless, much more information 
is needed on the potential uses of this index in the field 
of hepatology. More advanced stages of NAFLD appear to 
be associated with older age, higher BMI, diabetes, hy-
pertension, high triglycerides, and insulin resistance (9). 
The findings from different studies are not completely 
consistent as to which factors (including APRI score) are 
independently associated with fibrosis progression, and 
this may depend on the population studied.
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